Cargando…

Tardive dyskinesia with low dose amisulpride

In recent years, there has been an increasing trend to use amisulpride in the treatment of dysthymia and also as an adjunct treatment in patients with major depression. At low doses (50 mg), amisulpride preferentially blocks presynaptic auto receptors, enhances dopamine release, and therefore acts a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tharoor, Hema, Padmavati, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574463/
https://www.ncbi.nlm.nih.gov/pubmed/23440033
http://dx.doi.org/10.4103/0019-5545.105523
_version_ 1782259588065656832
author Tharoor, Hema
Padmavati, R.
author_facet Tharoor, Hema
Padmavati, R.
author_sort Tharoor, Hema
collection PubMed
description In recent years, there has been an increasing trend to use amisulpride in the treatment of dysthymia and also as an adjunct treatment in patients with major depression. At low doses (50 mg), amisulpride preferentially blocks presynaptic auto receptors, enhances dopamine release, and therefore acts as a dopaminergic compound able to resolve the dopaminergic hypo activity that characterizes depression. Based on experimental data, amisulpride is the drug of choice for dopaminergic transmission disorders, both in depression and in schizophrenia. This case highlights the development of dyskinesia in a depressed patient treated with low dose amisulpride and fluvoxamine.
format Online
Article
Text
id pubmed-3574463
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-35744632013-02-22 Tardive dyskinesia with low dose amisulpride Tharoor, Hema Padmavati, R. Indian J Psychiatry Case Report In recent years, there has been an increasing trend to use amisulpride in the treatment of dysthymia and also as an adjunct treatment in patients with major depression. At low doses (50 mg), amisulpride preferentially blocks presynaptic auto receptors, enhances dopamine release, and therefore acts as a dopaminergic compound able to resolve the dopaminergic hypo activity that characterizes depression. Based on experimental data, amisulpride is the drug of choice for dopaminergic transmission disorders, both in depression and in schizophrenia. This case highlights the development of dyskinesia in a depressed patient treated with low dose amisulpride and fluvoxamine. Medknow Publications & Media Pvt Ltd 2013 /pmc/articles/PMC3574463/ /pubmed/23440033 http://dx.doi.org/10.4103/0019-5545.105523 Text en Copyright: © Indian Journal of Psychiatry http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Tharoor, Hema
Padmavati, R.
Tardive dyskinesia with low dose amisulpride
title Tardive dyskinesia with low dose amisulpride
title_full Tardive dyskinesia with low dose amisulpride
title_fullStr Tardive dyskinesia with low dose amisulpride
title_full_unstemmed Tardive dyskinesia with low dose amisulpride
title_short Tardive dyskinesia with low dose amisulpride
title_sort tardive dyskinesia with low dose amisulpride
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3574463/
https://www.ncbi.nlm.nih.gov/pubmed/23440033
http://dx.doi.org/10.4103/0019-5545.105523
work_keys_str_mv AT tharoorhema tardivedyskinesiawithlowdoseamisulpride
AT padmavatir tardivedyskinesiawithlowdoseamisulpride